IMMUNO-ONCOLOGY THERAPEUTICS - Investment Environment

Although these days the race to develop a COVID-19 vaccine is taking centre stage in the current biosciences environment, oncology still plays a key role as being the next largest area for investment activity. Before COVID-19 struck, oncology represented nearly half of the buy-side transactions for the large pharma dealmakers, and topped US venture capital funding by disease area. Most oncology therapy deals are characterised by M&A (70%) whereas licensing makes up much less of the total (27%).

Our Q4 2020 report provides an in-depth analysis of this dynamic investment environment along with the latest developments in the field of immuno-oncology therapeutics.

Table of contents:

• Deal Landscape

• M&A Deals

• Licensing Deals

• Venture Capital

• Key Immuno-Oncology Therapies

• CAR-T

• CRISPR

• Neoantigen Vaccines

• Checkpoint Inhibitors

• Combination Therapies

• Biomarkers

• Companion Diagnostics

• Next Generation Sequencing

• Clinical Trials

You can download our report from here:

Friday_Capital_Report_Immuno_Oncology_Q4.

Download • 3.39MB

For further details and enquiries please contact Anthony Vago at anthony.vago@friday.capital.